Shanghai Fosun Pharmaceutical : APPOINTMENT OF VICE CHAIRMAN（H SHARES）

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

APPOINTMENT OF VICE CHAIRMAN

The Board announces that with effect from 4 January 2022:

1. Mr. Wang Kexin has been appointed as a vice chairman of the Board; and
2. Ms. Guan Xiaohui has been appointed as a vice chairman of the Board.

APPOINTMENT OF VICE CHAIRMAN

The board (the ''Board'') of directors (the ''Directors'') of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'', together with its subsidiaries, the ''Group'') announces that (i) Mr. Wang Kexin (''Mr. Wang'') was appointed as a vice chairman of the Board with effect from 4 January 2022, and (ii) Ms. Guan Xiaohui (''Ms. Guan'') was appointed as a vice chairman of the Board with effect from 4 January 2022.

Set forth below are the biographical details of Mr. Wang and Ms. Guan.

Mr. Wang Kexin (王可心先生)

Mr. Wang, aged 57, was appointed as a vice chairman of the Board on 4 January 2022 and an executive Director on 7 December 2021. Mr. Wang currently serves as director of certain subsidiaries of the Company. Mr. Wang joined the Group in June 2010, he served as the vice president and senior vice president of the Company, and has been served as the co-president and chief investment officer of the Company during the period from October 2020 to January 2022. Prior to joining the Group, Mr. Wang served as the deputy general manager of Haihong Holdings Pharmaceutical E-commerce Co., Ltd.* (海虹控股醫藥電子商務有限公司), the marketing director of Kunming Pharmaceutical (Group) Co., Ltd* (昆明製藥集團股份有限公司), a company listed on Shanghai Stock Exchange (stock code: 600422), the general manager of Kunming Pharmaceutical Sales Co., Ltd.* (昆明製藥藥品銷售有限公 司), the general manager of Beijing Huali Jiuzhou Pharmaceutical Co., Ltd.* (北京華立九州醫藥有限 公司), the vice president of Chongqing Huali Pharmaceutical Co., Ltd.* (重慶華立藥業股份有限公司),

- 1 -

a company previously listed on Shenzhen Stock Exchange (previous stock code: 000607), and the chairman of Beijing Tianren Hexin Pharmaceutical Management Co., Ltd.* (北京天仁合信醫藥經營有 限責任公司). Mr. Wang graduated from Shenyang Pharmaceutical University (formerly known as Shenyang Pharmaceutical College) with a bachelor's degree in pharmacy.

Mr. Wang has confirmed that, save as disclosed herein, as at the date of this announcement, he does not have any relationship with any directors, senior management or substantial shareholders of the Company, and does not hold any other positions in the Company or any subsidiaries of the Company nor any other directorships in listed companies in the last three years.

To the knowledge of the Directors, Mr. Wang has personal interests in 202,500 A shares of the Company (the ''A Shares'') within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (''SFO'') as at the date of this announcement, representing approximately 0.01% of the Company's total number of issued A Shares (i.e. 2,010,958,045 shares) and approximately 0.01% of the total number of issued shares of the Company (i.e. 2,562,898,545 shares). Save as disclosed above, Mr. Wang is not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

As at the date of this announcement, Mr. Wang has not entered into a service contract as a Director and the vice chairman of the Board with the Company. Mr. Wang will not receive any director's emolument from the Company for his appointment as a Director and a vice chairman of the Board but, will be entitled to remuneration, which is determined mainly based on corporate performance, taking into account of the positions held in the Group and the actual appraisal results as well as the prevailing market conditions, subject to the review and recommendation by the remuneration committee of the Board with reference to the remuneration policy of the Company and the shareholders' approval at the general meeting.

Ms. Guan Xiaohui (關曉暉女士)

Ms. Guan, aged 50, was appointed as a vice chairman of the Board on 4 January 2022 and an executive Director on 7 December 2021. Ms. Guan currently serves as director and supervisor of certain subsidiaries of the Company. Ms. Guan joined the Group in May 2000 and served as the financial manager of pharmaceutical circulation business department, the deputy chief financial officer, the commercial management committee deputy director, president assistant, general manager of the financial department, chief accountant, vice president and senior vice president of the Company, and has been served as the executive president and chief financial officer of the Company during the period

from October 2020 to January 2022. Ms. Guan currently also serves as director of Shanghai Fosun High Technology Group Finance Co., Ltd.* (上海復星高科技集團財務有限公司) and Fosun Health

Finance Lease (Shanghai) Co., Ltd.* (復星康健融資租賃(上海)有限公司), respectively, both are subsidiaries of Shanghai Fosun High Technology (Group) Co., Ltd.* (上海復星高科技(集團)有限公 司), the controlling shareholder of the Company. Prior to joining the Group, Ms. Guan worked at Jiangxi Branch of Industrial and Commercial Bank of China. Ms. Guan is currently a non-executive director of Shanghai Henlius Biotech, Inc., a company listed on the Hong Kong Stock Exchange (stock code: 02696) and a subsidiary of the Company, a non-executive director of Gland Pharma Limited, a company listed on the BSE Limited and the National Stock Exchange of India Limited (stock code: GLAND) and a subsidiary of the Company, and the chairman of the supervisory committee of Sinopharm Group Co., Ltd.* (國藥控股股份有限公司) (''Sinopharm''), a company listed on the Hong

- 2 -

Kong Stock Exchange (stock code: 01099). Ms. Guan served as a non-executive director of Sinopharm from March 2019 to March 2021. Ms. Guan graduated from Jiangxi University of Finance and Economics with a bachelor's degree in economics, and graduated from the Chinese University of Hong Kong with a master's degree of professional accountancy. Ms. Guan has the qualifications of a Chinese Certified Public Accountant (CPA) and is a member of the Association of Chartered Certified Accountants (ACCA).

Ms. Guan has confirmed that, save as disclosed herein, as at the date of this announcement, she does not have any relationship with any directors, senior management or substantial shareholders of the Company, and does not hold any other positions in the Company or any subsidiaries of the Company nor any other directorships in listed companies in the last three years.

To the knowledge of the Directors, Ms. Guan has personal interests in 181,000 A shares within the meaning of Part XV of the SFO as at the date of this announcement, representing approximately 0.01% of the Company's total number of issued A Shares (i.e. 2,010,958,045 shares) and approximately 0.01% of the total number of issued shares of the Company (i.e. 2,562,898,545 shares). Save as disclosed above, Ms. Guan is not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the SFO.

As at the date of this announcement, Ms. Guan has not entered into a service contract as a Director and vice chairman of the Board with the Company. Ms. Guan will not receive any director's emolument from the Company for her appointment as a Director and a vice chairman of the Board but, will be entitled to remuneration, which is determined mainly based on corporate performance, taking into account of the positions held in the Group and the actual appraisal results as well as the prevailing market conditions, subject to the review and recommendation by the remuneration committee of the Board with reference to the remuneration policy of the Company and the shareholders' approval at the general meeting.

Save as disclosed herein, the Board is not aware of any other matters in relation to the appointment of Mr. Wang and Ms. Guan as vice chairman of the Board that need to be brought to the attention of the Shareholders or any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the People's Republic of China

4 January 2022

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang, Mr. Wang Kexin and Ms. Guan Xiaohui; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

• For identification purposes only

- 3 -